Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1-anchored Bifidobacterium longum 420
- Development stage
- Unknown
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**WT1-anchored Bifidobacterium longum 420** is a genetically engineered oral protein vaccine platform, developed by anchoring the Wilms’ tumor 1 (WT1) protein, a tumor-associated antigen, onto the probiotic bacterium *Bifidobacterium longum* 420. This oral vaccine aims to induce intestinal immunity against cancer, particularly showing antitumor activity by activating WT1-specific immune responses. Oral administration of this vaccine in preclinical mouse models demonstrated significant tumor size reduction and activation of CD8+ T cells, along with enhanced activation of dendritic cells and increased production of WT1-specific antibodies. The vaccine uses the mucosal immune system via Peyer’s patches to prime systemic antitumor immunity, suggesting a novel intestinal bacterium-based cancer immunotherapy approach. This platform leverages the natural probiotic properties of *B. longum* 420 alongside engineered cancer antigen presentation to stimulate an effective antitumor immune response.
02
Targets
CD8A (CD8 alpha/beta Coreceptor)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT1-anchored Bifidobacterium longum 420.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1-anchored Bifidobacterium longum 420.